$128.56
+1.1%Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Acceptable margins but limited operational leverage. Operating expense control is important.
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
TFX โข NYSE
| Teleflex Incorporated Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
2B | 3B | 3B | 2.8B | 2.8B | 2.5B | 2.6B | 2.4B | 2.1B | 1.9B | 1.8B | 1.8B | 1.7B | 1.6B | 1.5B | 1.8B | 1.9B | 2.4B | 1.9B | 2.6B | |
GROSS PROFIT | ||||||||||||||||||||
(872M) | (1.3B) | (1.3B) | (1.3B) | (1.3B) | (1.2B) | (1.2B) | (1.1B) | (974.5M) | (871.8M) | (865.3M) | (897.4M) | (857.3M) | (802.8M) | (810.1M) | (1B) | (1.1B) | (1.5B) | (1.3B) | (1.9B) | |
1.1B | 1.7B | 1.6B | 1.5B | 1.5B | 1.3B | 1.4B | 1.4B | 1.2B | 996.2M | 944.4M | 942.4M | 838.9M | 748.2M | 718.8M | 794.1M | 814.1M | 964.2M | 680.4M | 774.2M | |
OPERATING INCOME | ||||||||||||||||||||
(865M) | (1.6B) | (1.1B) | (1B) | (921.5M) | (901.8M) | (981.8M) | (984.9M) | (784.7M) | (621.9M) | (621.1M) | (639.7M) | (567.2M) | (510.8M) | (478.6M) | (517.6M) | (522.5M) | (624.2M) | (445.3M) | (494.4M) | |
(720.2M) | (995.3M) | (929.9M) | (863.7M) | (860.1M) | (743.6M) | (851.8M) | (878.7M) | (700M) | (563.3M) | (569M) | (578.7M) | (502.2M) | (454.5M) | (429.3M) | (475.3M) | (519.9M) | (596.8M) | (445.3M) | (493.5M) | |
(144.8M) | (161.7M) | (154.4M) | (153.8M) | (130.8M) | (119.7M) | (113.9M) | (106.2M) | (84.8M) | (58.6M) | (52.1M) | (61M) | (65M) | (56.3M) | (48.7M) | (42.6M) | (0.0) | (0.0) | (30M) | (0.0) | |
255.8M | 151M | 506.3M | 499.7M | 628.1M | 423.1M | 427.3M | 321.7M | 372.3M | 319.5M | 315.9M | 284.9M | 233.3M | -97.4M | 233.2M | 273.6M | 269.8M | 340M | 192.6M | 254.6M | |
PRE-TAX INCOME | ||||||||||||||||||||
(100.2M) | (83.5M) | (85.1M) | (54.3M) | (57M) | (66.5M) | (80.3M) | (103M) | (82.5M) | (54.9M) | (61.3M) | (65.5M) | (56.9M) | (69.6M) | (70.3M) | (80M) | (89.5M) | (121.6M) | (0.0) | (0.0) | |
-93.8M | -75.5M | -72.3M | -53.4M | -55.6M | -65.3M | -78.5M | -102.1M | -81.8M | -54.5M | -60.8M | -64.8M | -56.3M | -68M | -69.1M | -79.1M | -86.9M | -119.3M | 0.0 | 0.0 | |
(0.0) | (394.7M) | (56.4M) | (13.8M) | -69.4M | (38.5M) | (16.1M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (582K) | -341K | (2.6M) | (2.3M) | (0.0) | (838K) | |
-231.3M | -75.5M | -72.3M | -53.8M | -68.6M | -65.3M | -87.4M | 23.2M | -87.4M | -73.7M | -71.2M | -64.8M | -57.5M | -181.8M | -84.5M | -82.5M | -86.9M | -119M | -83.3M | -35.9M | |
24.6M | 75.5M | 434M | 445.9M | 559.5M | 357.7M | 339.9M | 219.6M | 284.9M | 245.7M | 244.6M | 220.1M | 175.7M | -165.4M | 148.7M | 147.8M | 182.8M | 221M | 109.3M | 219M | |
NET INCOME | ||||||||||||||||||||
-34M | (5.3M) | (76.4M) | (83M) | (74.3M) | (21.9M) | -122.1M | (23.2M) | (129.6M) | (8.1M) | (7.8M) | (28.7M) | (23.5M) | (16.4M) | (27M) | (21.9M) | (39.9M) | (52.2M) | (122.8M) | (54.1M) | |
-905.6M | 69.7M | 356.3M | 363.1M | 485.4M | 335.3M | 461.5M | 200.8M | 152.5M | 237.4M | 244.9M | 187.7M | 150.9M | -190.1M | 323.3M | 201.1M | 303M | 119.8M | 146.5M | 139.4M |
TFX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 02, 2026 | June 01, 2026 | 2026 | |
8-K 8-K 2026 N/A | June 01, 2026 | June 01, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 27, 2026 | May 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 20, 2026 | May 15, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 28, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 13, 2026 | April 01, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 27, 2026 | March 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 17, 2026 | March 11, 2026 | 2026 |
Continue your TFX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.